Apart from HBOC, the germline BRCA1/2 mutations have also been found in a variety of other cancers, including pancreatic cancer [3], lung cancer [4], urothelial carcinoma [5] and esophageal cancer [6], etc. It is reasonable to expect that PARPi may also be effective for these patients. This evidence concerns the gene BRCA1 and lung cancer.